Please login to the form below
10
Revenue 2017Amgen
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Amgen's 2013 sales performance.
Date set for EU antitrust regulators to decide on Pfizer’s $43bn Seagen acquisition
At the time of the request, concern was rising among investors regarding the FTC’s decision to block Amgen’s proposed $27.8bn takeover of Horizon Therapeutics. ... The Amgen/Horizon transaction has since been allowed to proceed after a proposed
Novartis sues US government over Medicare drug price negotiation programme
Other drugs selected for negotiation were Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and Boehringer
Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement
The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction. ... Amgen said it has consistently stated that it has no reason, ability or intention to bundle Horizon’s two drugs with any of its products.
US government announces first ten drugs subject to Medicare pricing negotiations
The list includes Bristol Myers Squibb and Pfizer’s Eliquis (apixaban), Novartis' Entresto (valsartan/sacubitril), Amgen's Enbrel (etanercept), AstraZeneca's Farxiga (dapagliflozin), Merck &Co's Januvia (sitagliptin), Eli Lilly and
The rise of biologics: is the sector ready for future demand?
Today, leading biologics manufacturers such as Pfizer, BMS, Janssen, Amgen, Sanofi, Takeda, including leading emerging names like MeiraGTx, Horizon, Alexion, BioMarin, have their tech ops and manufacturing sites (bulk drug,
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
